C
Ching-Wei Chang
Researcher at Genentech
Publications - 27
Citations - 1098
Ching-Wei Chang is an academic researcher from Genentech. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 8, co-authored 13 publications receiving 581 citations.
Papers
More filters
Journal ArticleDOI
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.
Leisha A. Emens,Leisha A. Emens,Cristina Cruz,Joseph Paul Eder,Fadi Braiteh,Cathie Chung,Sara M. Tolaney,Irene Kuter,Rita Nanda,Philippe A. Cassier,Jean Pierre Delord,Michael S. Gordon,Ehab Elgabry,Ching-Wei Chang,Indrani Sarkar,William Grossman,Carol O'Hear,Marcella Fassò,Luciana Molinero,Peter Schmid +19 more
TL;DR: Single-agent atezolizumab was well tolerated and provided durable clinical benefit in patients with mTNBC with stable or responding disease and in earlier lines of treatment.
Journal ArticleDOI
Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial.
Sylvia Adams,Jennifer R. Diamond,Erika Hamilton,Paula R. Pohlmann,Sara M. Tolaney,Ching-Wei Chang,Wei Zhang,Koho Iizuka,Paul Foster,Luciana Molinero,Roel Funke,John D. Powderly +11 more
TL;DR: In this phase 1b trial for metastatic triple-negative breast cancers, the combination of atezolizumab plus nab-paclitaxel had a manageable safety profile and biomarker responses were observed, including in patients previously treated with a taxane.
Journal ArticleDOI
Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer.
Mélanie Desbois,Akshata Udyavar,Lisa Ryner,Cleopatra Kozlowski,Yinghui Guan,Milena Dürrbaum,Shan Lu,Jean-Philippe Fortin,Hartmut Koeppen,James Ziai,Ching-Wei Chang,Shilpa Keerthivasan,Marie Plante,Richard Bourgon,Carlos Bais,Priti S. Hegde,Anneleen Daemen,Shannon J. Turley,Yulei Wang +18 more
TL;DR: This study identifies two important hallmarks characterizing T cell excluded tumours: 1) loss of antigen presentation on tumour cells and 2) upregulation of TGFβ and activated stroma.
Journal ArticleDOI
Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts.
Katherine E. Hutchinson,Susan E. Yost,Ching-Wei Chang,Radia M. Johnson,Adrian R. Carr,Paul R. McAdam,Daniel L. Halligan,Chun-Chieh Chang,Daniel Schmolze,Jackson Liang,Yuan Yuan +10 more
TL;DR: In this article, the authors studied the genomic and transcriptomic profiles of paired tumors from patients with triple-negative breast cancers (TNBC), and observed a typical TNBC mutational landscape with minimal shifts in copy number or TMB over time.
Journal ArticleDOI
Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort.
Xiaoji Chen,Ching-Wei Chang,Jill M. Spoerke,Kathryn E. Yoh,Vidushi Kapoor,Charles D. Baudo,Junko Aimi,Mamie Yu,May M. Y. Liang-Chu,Rebecca Suttmann,Ling-Yuh Huw,Steven Gendreau,Craig Cummings,Mark R. Lackner +13 more
TL;DR: LP-WGS offers an unbiased and high-throughput way to investigate CNVs and tumor fraction in cfDNA of patients with cancer, and may also be valuable for monitoring treatment response, detecting disease progression early, and identifying emergent clones associated with therapeutic resistance.